JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级,下调目标价至41美元
分析师对以下医疗公司存在意见分歧:EyePoint Pharmaceuticals (EYPT),INmune Bio (INMB) 和 ICU医疗 (ICUI)
丰业银行维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价18美元
EyePoint Pharmaceuticals 分析师评级
TD Cowen维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价20美元
EyePoint Pharmaceuticals:强烈买入评级,得益于有前景的临床试验进展和市场潜力
瑞穗证券维持EyePoint Pharmaceuticals(EYPT.US)买入评级,目标价30美元
TD Cowen维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价20美元
分析师对医疗公司进行深入分析:OnKure Therapeutics (OKUR) 和 EyePoint Pharmaceuticals (EYPT)
JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级,下调目标价至42美元
EyePoint Pharmaceuticals 被Chardan Capital维持为买入
H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价22美元
EyePoint Pharmaceuticals的价格目标保持在每股22.00美元,由HC Wainwright & Co.维护。
EyePoint Pharmaceuticals 分析师评级
EyePoint Pharmaceuticals:有希望的临床进展和强大的财务状况证明了买入评级
丰业银行维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价18美元
加拿大丰业银行维持对EyePoint Pharmaceuticals (EYPT) 的买入评级
瑞穗证券维持EyePoint Pharmaceuticals(EYPT.US)买入评级
丰业银行维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价18美元
EyePoint Pharmaceuticals 分析师评级